Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

71.19 +0.56 (+0.79%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 13, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	3,506,917
Open	70.31
Bid (Size)	70.01 (200)
Ask (Size)	74.90 (100)
Prev. Close	70.63
Today's Range	70.22 - 72.66
52wk Range	42.01 - 79.50
Shares Outstanding	142,334,900
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Halozyme Stock Surging On Recent Earnings Beat; Record High Ahead? ↗

November 12, 2025

Halozyme also boasts a 98 Composite Rating out of 99. The best growth stocks have a Composite of 90 or better.

Via Investor's Business Daily

Halozyme Therapeutics Inc (NASDAQ:HALO) Shows Strong Growth and Technical Breakout Potential ↗

November 11, 2025

Discover Halozyme (HALO), a biotech stock with strong EPS growth, high profitability, and a bullish technical breakout pattern for potential gains.

Via Chartmill

Performance

YTD	+48.3%	+48.3%
1 Month	+9.0%	+9.0%
3 Month	+9.3%	+9.3%
6 Month	+48.6%	+48.6%
1 Year	+19.4%	+19.4%

More News

Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High

November 06, 2025

Via MarketMinute

Renaissance Group Opens New $35M Position in Halozyme Therapeutics (NASDAQ: HALO): Why This Biotech Stock Is Worth a Look ↗

November 05, 2025

Via The Motley Fool

Earnings Scheduled For November 3, 2025 ↗

November 03, 2025

Via Benzinga

Halozyme (HALO) Q3 2025 Earnings Call Transcript ↗

November 03, 2025

Via The Motley Fool

Insights into Halozyme Therapeutics's Upcoming Earnings ↗

October 31, 2025

Via Benzinga

Halozyme Therapeutics Inc (NASDAQ:HALO) Fits a Proven Growth Investing Method ↗

October 30, 2025

Via Chartmill

Koa Wealth Liquidates All 68K IIPR Shares Valued at $3.8 Million ↗

October 29, 2025

Via The Motley Fool

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Combines Strong Growth Momentum with Technical Breakout Setup ↗

October 27, 2025

Via Chartmill

Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a Compelling Value Investment Case ↗

October 25, 2025

Via Chartmill

Halozyme Therapeutics Inc (NASDAQ:HALO) Offers an Affordable Growth Profile ↗

October 21, 2025

Via Chartmill

Halozyme Therapeutics Inc (NASDAQ:HALO): A Growth Stock Poised for a Breakout ↗

October 18, 2025

Via Chartmill

The Analyst Verdict: Halozyme Therapeutics In The Eyes Of 10 Experts ↗

October 15, 2025

Via Benzinga

Halozyme Therapeutics Inc (NASDAQ:HALO) Demonstrates Strong Growth and Profitability ↗

October 09, 2025

Via Chartmill

Halozyme Therapeutics Inc (NASDAQ:HALO): A Prime Candidate for Affordable Growth ↗

September 26, 2025

Via Chartmill

Forecasting The Future: 7 Analyst Projections For Halozyme Therapeutics ↗

September 22, 2025

Via Benzinga

Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a High-Growth Momentum and Technical Breakout Opportunity ↗

September 20, 2025

Via Chartmill

Halozyme Therapeutics Inc (NASDAQ:HALO) Embodies Navellier's Growth Investing Principles ↗

September 17, 2025

Via Chartmill

Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a Compelling Case for Value Investors ↗

September 15, 2025

Via Chartmill

United Therapeutics Price Strength Rating Jumps After Its Stock Soared 33% Last Week On Positive Drug Test Results ↗

September 10, 2025

Via Investor's Business Daily

Halozyme Therapeutics Inc (NASDAQ:HALO) Fits Minervini's Trend Template with Strong Technicals and Earnings Momentum ↗

September 09, 2025

Via Chartmill

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Offers Affordable Growth With Strong Fundamentals ↗

September 05, 2025

Via Chartmill

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Stands Out in Navellier's Growth Screen ↗

August 27, 2025

Via Chartmill

Argenx Stock Hits Record High After Reporting 664% Earnings Surge; This Rating Upgraded ↗

August 26, 2025

Via Investor's Business Daily

Frequently Asked Questions

Is Halozyme Therapeutics, Inc. - Common Stock publicly traded?

Yes, Halozyme Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Halozyme Therapeutics, Inc. - Common Stock trade on?

Halozyme Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Halozyme Therapeutics, Inc. - Common Stock?

The ticker symbol for Halozyme Therapeutics, Inc. - Common Stock is HALO on the Nasdaq Stock Market

What is the current price of Halozyme Therapeutics, Inc. - Common Stock?

The current price of Halozyme Therapeutics, Inc. - Common Stock is 71.19

When was Halozyme Therapeutics, Inc. - Common Stock last traded?

The last trade of Halozyme Therapeutics, Inc. - Common Stock was at 11/13/25 04:00 PM ET

What is the market capitalization of Halozyme Therapeutics, Inc. - Common Stock?

The market capitalization of Halozyme Therapeutics, Inc. - Common Stock is 10.13B

How many shares of Halozyme Therapeutics, Inc. - Common Stock are outstanding?

Halozyme Therapeutics, Inc. - Common Stock has 10B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.